# Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis

> **NCT04818671** · PHASE3 · COMPLETED · sponsor: **argenx** · enrollment: 184 (actual)

## Conditions studied

- Generalized Myasthenia Gravis

## Interventions

- **BIOLOGICAL:** efgartigimod PH20 SC

## Key facts

- **NCT ID:** NCT04818671
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-26
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 184 (ACTUAL)
- **Last updated:** 2026-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04818671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04818671, "Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04818671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*